Xiaokui Mo

This record appears to reflect a name shared across many unrelated biomedical research efforts rather than a single coherent research program, spanning cancer immunotherapy, clinical trials in leukemia and sarcoma, cartilage/osteoarthritis biology, nanomedicine, and chemistry. The publication list touches on topics like CAR-T and immune cell therapies in cancer, lymphoma treatment, and gut microbiota, but the recent titles suggest contributions as a co-author (possibly a biostatistician or clinical trial collaborator) across many distinct projects rather than a focused independent lab. Prospective students should verify with the institution whether this profile corresponds to a single PI with a defined lab or a shared/co-author name across multiple groups.

Publication output was relatively steady (13-29 papers/year) from 2017-2022, then spiked sharply in 2023 (135) before settling into elevated but variable levels in 2024-2025, suggesting a growing and increasingly collaborative publication footprint in recent years.

Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026